TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
03 Enero 2022 - 3:05PM
Business Wire
TYME Technologies, Inc. (Nasdaq: TYME) (the
Company or TYME), an emerging biotechnology company developing
cancer metabolism-based therapies (CMBTs™), today announced that
Richie Cunningham, Chief Executive Officer, and Jonathan Eckard,
Chief Business Officer, will present at the H.C. Wainwright
Bioconnect Virtual Conference as follows:
Date:
Monday, January 10, 2022
On Demand:
7:00AM ET
Webcast:
https://journey.ct.events/view/8689e139-56fc-489f-a7ff-f600798ac5b3
The presentation will be available on demand beginning on
January 10, 2022, at 7:00 a.m. ET and will be accessible on the
Events & Presentations page of the Investors
section of the TYME website, tymeinc.com, and will be
archived for 90 days following the event.
About TYME Technologies, Inc. TYME is an emerging
biotechnology company developing cancer metabolism-based therapies
(CMBTs™) that are intended to be effective across a broad range of
solid tumors and hematologic cancers, while also maintaining
patients’ quality of life through relatively low toxicity profiles.
Unlike targeted therapies that attempt to regulate specific
mutations within cancer, the Company’s therapeutic approach is
designed to take advantage of a cancer cell’s innate metabolic
weaknesses to cause cancer cell death.
The Company is currently developing its lead novel compound,
SM-88. The Company believes that early clinical results
demonstrated by SM-88 in multiple advanced cancers, including
pancreatic, prostate, sarcomas and breast, reinforce the potential
of its emerging CMBT™ pipeline.
For more information about the Company, visit www.tymeinc.com
and connect on Facebook, LinkedIn, and Twitter.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements under the Private Securities
Litigation Reform Act that involve substantial risks and
uncertainties. The forward-looking statements contained in this
press release are based on management's current expectations, which
are subject to uncertainty, risks and changes in circumstances that
are difficult to predict and many of which are outside of TYME's
control. Factors that could cause actual results to differ
materially from these forward-looking statements include the
Company’s ability to successfully implement its clinical and other
plans, competitive and regulatory developments, and the factors
described in the section captioned “Risk Factors” of TYME’s Annual
Report on Form 10-K filed with the U.S. Securities and Exchange
Commission (“SEC”) on June 10, 2021, as well as subsequent reports
and filings from time to time with the SEC.
The information contained in this press release is as of release
date and TYME assumes no obligation to update forward-looking
statements contained in this release as a result of future events
or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005237/en/
INVESTOR AND MEDIA CONTACT:
In-Site Communications Lisa M. Wilson T: 212-452-2793 E:
lwilson@insitecony.com
Tyme Technologies (NASDAQ:TYME)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Tyme Technologies (NASDAQ:TYME)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024